ATE273305T1 - Thrombin-inhibitoren - Google Patents

Thrombin-inhibitoren

Info

Publication number
ATE273305T1
ATE273305T1 AT99962534T AT99962534T ATE273305T1 AT E273305 T1 ATE273305 T1 AT E273305T1 AT 99962534 T AT99962534 T AT 99962534T AT 99962534 T AT99962534 T AT 99962534T AT E273305 T1 ATE273305 T1 AT E273305T1
Authority
AT
Austria
Prior art keywords
thrombin inhibitors
formula
anticoagulants
class
compounds
Prior art date
Application number
AT99962534T
Other languages
English (en)
Inventor
Koo Lee
Won Hyuk Jung
Cheol Won Park
Sang Koo Lee
Sun Hwa Lee
Hee Dong Park
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Application granted granted Critical
Publication of ATE273305T1 publication Critical patent/ATE273305T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
AT99962534T 1998-12-29 1999-12-29 Thrombin-inhibitoren ATE273305T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19980060266 1998-12-29
KR1019990033490A KR20000047461A (ko) 1998-12-29 1999-08-14 트롬빈 억제제
PCT/KR1999/000830 WO2000039124A1 (en) 1998-12-29 1999-12-29 Thrombin inhibitors

Publications (1)

Publication Number Publication Date
ATE273305T1 true ATE273305T1 (de) 2004-08-15

Family

ID=26634497

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99962534T ATE273305T1 (de) 1998-12-29 1999-12-29 Thrombin-inhibitoren

Country Status (22)

Country Link
US (2) US6492402B1 (de)
EP (1) EP1140918B1 (de)
JP (1) JP3847092B2 (de)
KR (2) KR20000047461A (de)
CN (1) CN1149210C (de)
AT (1) ATE273305T1 (de)
AU (1) AU765417B2 (de)
BR (1) BR9916678A (de)
CA (1) CA2355281A1 (de)
CZ (1) CZ20012429A3 (de)
DE (1) DE69919397T2 (de)
DK (1) DK1140918T3 (de)
ES (1) ES2226482T3 (de)
HK (1) HK1044936A1 (de)
HU (1) HUP0104500A3 (de)
IL (1) IL143545A (de)
NO (1) NO321739B1 (de)
NZ (1) NZ513174A (de)
RU (1) RU2221808C2 (de)
TR (1) TR200101899T2 (de)
WO (1) WO2000039124A1 (de)
ZA (1) ZA200104780B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1046289A1 (zh) * 1999-04-09 2003-01-03 Abbott Gmbh & Co. Kg 凝血酶抑制剂的前体药物
DE19933861A1 (de) 1999-07-23 2001-01-25 Basf Ag Verfahren zur Herstellung von 2-Aminomethyl-4-cyano-thiazol
DE19934066A1 (de) * 1999-07-23 2001-01-25 Basf Ag Verfahren zur Herstellung von 4-Cyano-2-aminomethylthiazol
DE10049937A1 (de) * 2000-10-06 2002-04-11 Knoll Ag Niedermolekulare Inhibitoren von Serinproteasen mit Polyhydroxyalkyl- und Polyhydroxycycloalkylresten
KR100447421B1 (ko) 2001-04-04 2004-09-07 주식회사 엘지생명과학 5-(아미노메틸)-2-티오펜카보니트릴 염산염의 연속반응에의한 새로운 제조방법
BR0308525A (pt) * 2002-03-22 2005-02-01 Lg Life Sciences Ltd Formas cristalinas
JP2005526801A (ja) * 2002-03-22 2005-09-08 エルジー・ライフ・サイエンシーズ・リミテッド （２ｓ）−ｎ−｛５−［アミノ（イミノ）メチル］−２−チエニル｝メチル−１−｛［（２ｒ）−２−［（カルボキシルメチル）アミノ］−３，３−ジフェニルプロパノイル］｝−２−ピロリジンカルボキサミドマレイン酸塩及びそれらの製造方法
AU2003245060A1 (en) * 2002-06-27 2004-01-19 Lg Life Sciences Ltd. Peptidic thrombin inhibitor compound
US7097967B2 (en) 2002-10-24 2006-08-29 Lg Life Sciences Ltd. Method of predicting drug-food interaction
US7399870B2 (en) * 2004-03-30 2008-07-15 Wyeth Synthesis of pyrrole-2-carbonitriles
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US7678917B2 (en) * 2005-09-01 2010-03-16 Hoffman-La Roche Inc. Factor Xa inhibitors
DE602006021205D1 (de) 2005-10-07 2011-05-19 Exelixis Inc Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
JP2009538327A (ja) 2006-05-23 2009-11-05 アイアールエム・リミテッド・ライアビリティ・カンパニー チャネル活性化プロテアーゼ阻害剤である化合物および組成物
US20080287687A1 (en) * 2006-11-03 2008-11-20 Ajinomoto Co. Inc Production method of diphenylalanine-Ni (II) complex
BRPI0807483A2 (pt) 2007-02-09 2014-05-13 Irm Llc Compostos e composições como inibidores de protease de ativação de canal
WO2008135525A2 (en) * 2007-05-02 2008-11-13 Boehringer Ingelheim International Gmbh Substituted azetidines, manufacturing and use thereof as medicaments
EP2560966B1 (de) 2010-03-30 2021-01-06 Verseon International Corporation Mehrfach substituierte aromatische verbindungen als thrombinhemmer
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
JP6300042B2 (ja) 2012-10-12 2018-03-28 エグゼリクシス， インコーポレイテッド 癌の処置に使用するための化合物の製造方法
ES2853483T3 (es) 2013-03-15 2021-09-16 Verseon Int Corporation Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa
EP2970141B1 (de) 2013-03-15 2020-02-26 Verseon Corporation Halogenpyrazole als thrombinhemmer
BR112017004704A2 (pt) 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
US10532995B2 (en) 2015-02-27 2020-01-14 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
KR20210016545A (ko) * 2018-05-29 2021-02-16 오메로스 코포레이션 Masp-2 억제제 및 사용 방법
EP3847174A4 (de) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. Morphische formen von komplementfaktor-d-inhibitoren
JP2022502500A (ja) 2018-09-25 2022-01-11 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ阻害剤の形態
JP7471300B2 (ja) 2018-12-17 2024-04-19 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体介在性疾患を治療するための的を絞った投与
EP3941462A4 (de) 2019-03-22 2023-04-05 Achillion Pharmaceuticals, Inc. Pharmazeutische verbindungen zur behandlung von komplementvermittelten erkrankungen
WO2021113682A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
WO2021113686A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
EP4069676A1 (de) 2019-12-04 2022-10-12 Omeros Corporation Masp-2-hemmer und verfahren zur verwendung
JP7764808B2 (ja) * 2021-08-11 2025-11-06 Jsr株式会社 液晶配向剤、液晶配向膜及びその製造方法、液晶素子並びに重合体
WO2023183405A2 (en) * 2022-03-22 2023-09-28 Alexion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
EA002767B1 (ru) 1995-02-10 2002-08-29 Басф Акциенгезельшафт Ингибиторы тромбина
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5914319A (en) * 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
SA96170106A (ar) * 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
KR100689923B1 (ko) * 1998-01-26 2007-03-09 애보트 게엠베하 운트 콤파니 카게 트롬빈 억제제
WO1999037611A1 (de) * 1998-01-26 1999-07-29 Basf Aktiengesellschaft Heterocyclische amidine als kallikrein protease inhibitoren

Also Published As

Publication number Publication date
IL143545A (en) 2005-08-31
NO321739B1 (no) 2006-06-26
CN1149210C (zh) 2004-05-12
US6864249B2 (en) 2005-03-08
CA2355281A1 (en) 2000-07-06
TR200101899T2 (tr) 2001-12-21
DE69919397D1 (de) 2004-09-16
KR20010086468A (ko) 2001-09-12
CZ20012429A3 (cs) 2001-10-17
AU765417B2 (en) 2003-09-18
HUP0104500A3 (en) 2002-06-28
WO2000039124A1 (en) 2000-07-06
US6492402B1 (en) 2002-12-10
KR100462974B1 (ko) 2004-12-23
HUP0104500A2 (hu) 2002-04-29
DE69919397T2 (de) 2005-07-28
CN1332737A (zh) 2002-01-23
EP1140918B1 (de) 2004-08-11
KR20000047461A (ko) 2000-07-25
NO20013220D0 (no) 2001-06-27
NZ513174A (en) 2003-10-31
JP3847092B2 (ja) 2006-11-15
ZA200104780B (en) 2003-06-12
DK1140918T3 (da) 2004-12-20
US20030134801A1 (en) 2003-07-17
IL143545A0 (en) 2002-04-21
ES2226482T3 (es) 2005-03-16
RU2221808C2 (ru) 2004-01-20
HK1044936A1 (zh) 2002-11-08
BR9916678A (pt) 2001-10-16
JP2002533460A (ja) 2002-10-08
EP1140918A1 (de) 2001-10-10
AU1895100A (en) 2000-07-31
NO20013220L (no) 2001-08-27

Similar Documents

Publication Publication Date Title
ATE273305T1 (de) Thrombin-inhibitoren
ATE297203T1 (de) Antithrombotische mitteln
CY1107634T1 (el) Φαρμακευτικη συνθεση
ATE306261T1 (de) Antithrombosemittel
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
ATE272633T1 (de) Aromatische amiden
NO20003018L (no) Triazinangiogenese-inhibitorer
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
EE200200045A (et) Asendatud oksoasaheterotsüklüülühendid, farmatseutiline kompositsioon ja vaheühendid
NO991494D0 (no) <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer
TR200002182T2 (tr) İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
DE69931393D1 (de) Antithrombotische amide
ID18143A (id) Penghambat metaloprotease amina siklik tersubstitusi
SE9203825L (sv) Dubbelt verkande inhibitorer foer no-syntas och cyklooxygenas, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma
WO2003082205A3 (en) Compounds and methods
EA200500312A1 (ru) Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз
DK0715623T3 (da) Blodpladeaggregationsinhibitorer
UY26780A1 (es) Cicloalquil avb3 antagonistas
CO5261493A1 (es) Procedimiento y compuestos para la inhibicion de la mrp1
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
ATE308540T1 (de) Antithrombosemittel
DK0804418T3 (da) Platelataggregationshæmmere
ATE253359T1 (de) Antithrombotische mittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140918

Country of ref document: EP

REN Ceased due to non-payment of the annual fee